Why monkey studies may mislead research on cancer immunotherapy drugs targeting TIGIT

A new study published in the Journal of Biological Chemistry from UC Davis Comprehensive Cancer Center finds that TIGIT, an immune checkpoint receptor targeted by cancer immunotherapy drugs, triggers a different response in rhesus macaques compared to humans. The findings could have implications for cancer immunotherapy drugs targeting TIGIT.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup